ONS - Oncobiologics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Oncobiologics, Inc.

7 Clarke Drive
Cranbury, NJ 08512
United States
609-619-3990
http://www.oncobiologics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees48

Key Executives

NameTitlePayExercisedYear Born
Dr. Pankaj MohanFounder, Chairman, Pres & CEO1.39MN/A1965
Mr. Lawrence A. KenyonCFO, Principal Accounting Officer & Corp. Sec.327.09kN/A1966
Dr. Kenneth M. BahrtChief Medical OfficerN/AN/A1953
Rick GregoryDirector of Marketing & CommunicationsN/AN/AN/A
Dr. Stephen J. McAndrewSr. VP of Bus. Strategy & Devel.N/AN/A1954
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Oncobiologics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. Its advanced product candidate is ONS-3010, an adalimumab biosimilar that is in a Phase 1 clinical trial, which targets the tumor necrosis factor alpha. The company also develops ONS-1045, a bevacizumab biosimilar, which is in a Phase 1 clinical trial that interferes with tumor growth by binding to vascular endothelial growth factor, a protein that stimulates the formation of new blood vessels. Its advanced preclinical product candidate is ONS-1050, a trastuzumab biosimilar, interferes with the human epidermal growth factor receptor 2, a protein that stimulates cell proliferation. Oncobiologics, Inc. has collaboration and license agreements with Selexis SA; IPCA Laboratories Limited; Laboratories Liomont, S.A. de C.V.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.

Corporate Governance

Oncobiologics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.